As a promising example, in a phase II trial for an AE37 vaccine (NCT00524277), patients with advanced-stage breast cancer and HER2 low expression had a 5-year estimated DFS of 83% on the treated arm compared with a 62.5% in the GM-CSF alone arm (p = 0.039, HR 0.375, CI 0.142–0.988) [52,53,54]. This evidence concerns the gene CSF2 and breast carcinoma.